# EXL01 listing is produced correctly

    Code
      result
    Output
      Listing of Exposure to Study Drug
      
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————
                                          Study Day   Study Day                                                          
      Center/Subject ID       Visit         From         To         Treatment      Dose   Unit   Frequency      Route    
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      BRA-1/id-105        SCREENING       -1          -1          A: Drug X        960    mg     ONCE        INTRAVENOUS 
                          BASELINE        1           1           A: Drug X        960    mg     ONCE        INTRAVENOUS 
                          WEEK 1 DAY 8    8           8           A: Drug X        720    mg     ONCE        SUBCUTANEOUS
                          WEEK 2 DAY 15   15          15          A: Drug X        480    mg     ONCE        INTRAVENOUS 
                          WEEK 3 DAY 22   22          22          A: Drug X        480    mg     ONCE        INTRAVENOUS 
                          WEEK 4 DAY 29   29          29          A: Drug X        720    mg     ONCE        INTRAVENOUS 
                          WEEK 5 DAY 36   36          36          A: Drug X        720    mg     ONCE        INTRAVENOUS 
      BRA-1/id-134        SCREENING       -1          -1          A: Drug X        960    mg     ONCE        INTRAVENOUS 
                          BASELINE        1           1           A: Drug X        720    mg     ONCE        INTRAVENOUS 
                          WEEK 1 DAY 8    8           8           A: Drug X        720    mg     ONCE        INTRAVENOUS 
                          WEEK 2 DAY 15   15          15          A: Drug X        960    mg     ONCE        INTRAVENOUS 
                          WEEK 3 DAY 22   22          22          A: Drug X        720    mg     ONCE        INTRAVENOUS 
                          WEEK 4 DAY 29   29          29          A: Drug X        960    mg     ONCE        INTRAVENOUS 
                          WEEK 5 DAY 36   36          36          A: Drug X        960    mg     ONCE        INTRAVENOUS 
      BRA-1/id-141        SCREENING       -1          -1          C: Combination   960    mg     ONCE        INTRAVENOUS 
                          BASELINE        1           1           C: Combination   720    mg     ONCE        SUBCUTANEOUS
                          WEEK 1 DAY 8    8           8           C: Combination   720    mg     ONCE        INTRAVENOUS 
                          WEEK 2 DAY 15   15          15          C: Combination   960    mg     ONCE        INTRAVENOUS 
                          WEEK 3 DAY 22   22          22          C: Combination   1200   mg     ONCE        INTRAVENOUS 
                          WEEK 4 DAY 29   29          29          C: Combination   1200   mg     ONCE        INTRAVENOUS 
                          WEEK 5 DAY 36   36          36          C: Combination   1200   mg     ONCE        INTRAVENOUS 
      BRA-1/id-236        SCREENING       -1          -1          B: Placebo       960    mg     ONCE        INTRAVENOUS 
                          BASELINE        1           1           B: Placebo       720    mg     ONCE        INTRAVENOUS 
                          WEEK 1 DAY 8    8           8           B: Placebo       480    mg     ONCE        INTRAVENOUS 
                          WEEK 2 DAY 15   15          15          B: Placebo       720    mg     ONCE        INTRAVENOUS 
                          WEEK 3 DAY 22   22          22          B: Placebo       960    mg     ONCE        INTRAVENOUS 
                          WEEK 4 DAY 29   29          29          B: Placebo       1200   mg     ONCE        SUBCUTANEOUS
                          WEEK 5 DAY 36   36          36          B: Placebo       1440   mg     ONCE        INTRAVENOUS 
      BRA-1/id-265        SCREENING       -1          -1          C: Combination   960    mg     ONCE        INTRAVENOUS 
                          BASELINE        1           1           C: Combination   960    mg     ONCE        INTRAVENOUS 
                          WEEK 1 DAY 8    8           8           C: Combination   960    mg     ONCE        INTRAVENOUS 
                          WEEK 2 DAY 15   15          15          C: Combination   720    mg     ONCE        INTRAVENOUS 
                          WEEK 3 DAY 22   22          22          C: Combination   720    mg     ONCE        INTRAVENOUS 
                          WEEK 4 DAY 29   29          29          C: Combination   720    mg     ONCE        INTRAVENOUS 
                          WEEK 5 DAY 36   36          36          C: Combination   960    mg     ONCE        INTRAVENOUS 
      BRA-1/id-42         SCREENING       -1          -1          A: Drug X        960    mg     ONCE        INTRAVENOUS 
                          BASELINE        1           1           A: Drug X        960    mg     ONCE        INTRAVENOUS 
                          WEEK 1 DAY 8    8           8           A: Drug X        720    mg     ONCE        SUBCUTANEOUS
                          WEEK 2 DAY 15   15          15          A: Drug X        720    mg     ONCE        INTRAVENOUS 
                          WEEK 3 DAY 22   22          22          A: Drug X        720    mg     ONCE        INTRAVENOUS 
                          WEEK 4 DAY 29   29          29          A: Drug X        480    mg     ONCE        INTRAVENOUS 
                          WEEK 5 DAY 36   36          36          A: Drug X        480    mg     ONCE        INTRAVENOUS 
      BRA-1/id-65         SCREENING       -1          -1          B: Placebo       960    mg     ONCE        INTRAVENOUS 
                          BASELINE        1           1           B: Placebo       1200   mg     ONCE        INTRAVENOUS 
                          WEEK 1 DAY 8    8           8           B: Placebo       1440   mg     ONCE        INTRAVENOUS 
                          WEEK 2 DAY 15   15          15          B: Placebo       1200   mg     ONCE        INTRAVENOUS 
                          WEEK 3 DAY 22   22          22          B: Placebo       1440   mg     ONCE        INTRAVENOUS 
                          WEEK 4 DAY 29   29          29          B: Placebo       1440   mg     ONCE        INTRAVENOUS 
                          WEEK 5 DAY 36   36          36          B: Placebo       1440   mg     ONCE        INTRAVENOUS 
      BRA-1/id-93         SCREENING       -1          -1          A: Drug X        960    mg     ONCE        INTRAVENOUS 

